The USA-based company's strategy includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology.

Rain’s product candidate, milademetan, is a small molecule, oral inhibitor of the MDM2-p53 complex that reactivates p53.